NFE2L2 and lung carcinoma: In particular, Wang et al.4 showed that different anti-cancer drugs displayed disparate degrees of NRF2 activation and AKR1C overexpression in A549 lung carcinoma cells, including drugs with no effect (i.e., methotrexate), a modest (i.e., cisplatin), or strong effect (i.e., BCNU).